ClinicalTrials.gg
Active, not recruitingNCT07214779MAESTRA 2Updated Nov 17, 2026

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

A Phase 3 interventional study of INCB123667 and Investigator's choice of chemotherapy in Ovarian Cancer, sponsored by Incyte Corporation. Active, not recruiting at 198 sites in 16 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now Active, not recruitingPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Ovarian Neoplasms by Incyte Corporation — 2 open to participants now, 3 under way, 2 of them phase 3. Ovarian Neoplasms · Incyte Corporation.

Enrollment
15th of 17
13 · median 83
Started
2025
with 1 other
Phase 3
2 of 17
1 open now
Registered
16th of 17
by date

Among the 17 studies in Ovarian Neoplasms by Incyte Corporation, this one is the 15th largest by enrollment, is one of 2 that started in 2025, is one of 2 in phase 3, and was the 16th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

2 of the 17 studies in Ovarian Neoplasms by Incyte Corporation are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ovarian Neoplasms by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • INCB123667
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Have platinum-resistant disease.

    • Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum containing regimen.
    • Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.
  • Archival FFPE tumor tissue block or slides from a specimen no older than 5 years must be available. If not available, participant must be willing to undergo a pretreatment tumor .
  • Received at least 1 and no more than 4 following the initial diagnosis, after which single-agent chemotherapy is considered an appropriate next therapeutic option.
  • Should have received prior treatment with bevacizumab unless there was a for its use.
  • Should have received prior treatment with mirvetuximab soravtansine if the tumor is positive for FRα, unless there is an exception for its use on medical grounds.
  • per v1.1.

Exclusion criteria

Exclusion Criteria:

  • Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer.
  • Have primary platinum- disease, defined as progression on or within 3 months after the last dose of platinum-containing therapy.
  • or uncontrolled cardiac disease within 6 months before the first dose of study treatment.
  • Known active and/or carcinomatous meningitis.
  • Known additional that is progressing or requires active treatment, or history of other malignancy within 3 years before the first dose of study treatment.
  • Clinically significant gastrointestinal abnormalities.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Treatment Group A (TGA)

    INCB123667 at the protocol-defined dose.

    Drug: INCB123667

  • Experimental
    Treatment Group B (TGB)

    Investigator's choice of chemotherapy at the protocol-defined dose as defined by the protocol.

    Drug: Investigator's choice of chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) by BICR

    Defined as the time from the date of randomization until the earliest date of disease progression as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  2. Overall Survival (OS)

    Defined as the time from the date of randomization until death due to any cause.

    Time frame: Up to 2 years

Secondary outcomes

  1. Objective response by BICR

    Defined as having a best overall response of complete response (CR) or partial response (PR), as determined by BICR per RECIST v1.1.

    Time frame: Up to 2 years

  2. Duration of Response (DOR) by BICR

    Defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by BICR per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  3. Progression-Free Survival (PFS) by investigator

    Defined as the time from the date of randomization until the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  4. Objective response by investigator

    Defined as having a best overall response of CR or PR, as determined by investigator assessment per RECIST v1.1.

    Time frame: Up to 2 years

  5. DOR by investigator

    Defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  6. Treatment Emergent Adverse Events (TEAEs)

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug until 30 days after the last dose of study drug or the start of new anticancer therapy, whichever occurs first.

    Time frame: Up to 2 years and 30 days

  7. TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment

    TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment.

    Time frame: Up to 2 years and 30 days

  8. Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 (C30) at each postbaseline visit

    The EORTC QLQ-C30 is a validated, self-administered questionnaire developed to assess the quality of life in cancer patients. It consists of 30 questions divided into several subscales, including 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and a number of single-item measures that assess additional symptoms such as dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties.

    Time frame: Up to 2 years

  9. Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 28 (C28) score at each postbaseline visit

    The EORTC QLQ-OV28 is a validated, self-administered questionnaire developed as a supplementary module to the core QLQ-C30, specifically designed to assess HRQoL in participants with ovarian cancer. It contains 28 questions across several subscales, including 5 symptom scales (abdominal/gastrointestinal, peripheral neuropathy, hormonal/menopausal, chemotherapy side effects, and attitudes towards disease/treatment), 2 functional scales (body image and sexual functioning), and a number of single-item measures addressing issues such as other abdominal symptoms and hair loss.

    Time frame: Up to 2 years

  10. Change from baseline in EQ-5D-5L score at each postbaseline visit

    The EQ-5D-5L is a validated, self-reported instrument for assessing HRQoL across 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response levels of severity, ranging from no problems to extreme problems. The questionnaire also includes a visual analog scale for self-rated overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Up to 2 years

07

Study locations

198 sites

Showing the first 100 of 198 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 22 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Nov 2028 → Oct 2027 and completion May 2029 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Oct 9, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Oct 12, 2027was Nov 2028
CompletionEst.
Oct 12, 2027was May 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 17, 2026
Sites
7 sites added, 1 site removed. 119 sites changed recruiting status (111 now completed, 8 now recruiting)
Show 119 sites
  • Alaska Womens Cancer Care Akwcc · Anchorage, United StatesNot yet recruiting→Completed
  • University of Arizona Cancer Center · Tucson, United StatesNot yet recruiting→Completed
  • City of Hope Medical Center · Duarte, United StatesNot yet recruiting→Recruiting
  • Providence Medical Foundation · Fullerton, United StatesNot yet recruiting→Completed
  • University of California, San Diego-Moores Cancer Center · La Jolla, United StatesNot yet recruiting→Completed
  • Uci Health Chao Family Comprehensive Cancer Center · Orange, United StatesNot yet recruiting→Completed
  • Ventura County Hematology Oncology Specialists-Oxnard · Oxnard, United StatesNot yet recruiting→Completed
  • University of Colorado Cancer Center · Aurora, United StatesNot yet recruiting→Completed
  • Brcr Global · Miramar, United StatesNot yet recruiting→Completed
  • Sarasota Memorial Health Care System · Sarasota, United StatesNot yet recruiting→Completed
  • Winship Cancer Institute At Emory University · Atlanta, United StatesNot yet recruiting→Completed
  • Georgia Cancer Center · Augusta, United StatesNot yet recruiting→Completed
  • The University of Chicago Medicine · Chicago, United StatesNot yet recruiting→Completed
  • Carle Cancer Center · Effingham, United StatesNot yet recruiting→Completed
  • Northshore University Health System-Evanston Hospital · Evanston, United StatesNot yet recruiting→Completed
  • City of Hope - Chicago Cancer Center · Zion, United StatesNot yet recruiting→Completed
  • St Elizabeth Healthcare · Edgewood, United StatesNot yet recruiting→Completed
  • Maine Center For Cancer Medicine · Scarborough, United StatesNot yet recruiting→Completed
  • Holy Cross Hospital · Silver Spring, United StatesNot yet recruiting→Completed
  • Henry Ford Cancer - Detroit · Detroit, United StatesNot yet recruiting→Completed
  • Mercy Hospital St. Louis - David C. Pratt Cancer Center · St Louis, United StatesNot yet recruiting→Completed
  • Women'S Cancer Center of Nevada · Las Vegas, United StatesNot yet recruiting→Completed
  • Center of Hope · Reno, United StatesNot yet recruiting→Completed
  • Unm Comprehensive Cancer Center · Albuquerque, United StatesNot yet recruiting→Completed
  • East Carolina University · Greenville, United StatesNot yet recruiting→Completed
  • Cleveland Clinic Foundation · Cleveland, United StatesNot yet recruiting→Completed
  • Ohio Health Research Institute · Columbus, United StatesNot yet recruiting→Completed
  • Miami Valley Hospital South · Dayton, United StatesNot yet recruiting→Completed
  • Promedica Flower Hospital · Sylvania, United StatesNot yet recruiting→Completed
  • Providence Cancer Institute Franz Clinic · Portland, United StatesNot yet recruiting→Recruiting
  • …and 89 more on the registry record
Show 7 added (7 United States)
  • Mount Sinai Medical Center Comprehensive Cancer Center · Miami Beach, United States
  • Greater Baltimore Medical Center · Towson, United States
  • Penn State Milton S. Hershey Medical Center · Hershey, United States
  • Texas Oncology Cancer Center · Austin, United States
  • Texas Oncology, P.A., San Antonio Medical Center - Uso · San Antonio, United States
  • Texas Oncology (Txo) Northeast Texas (Tyler) · Tyler, United States
  • Providence Sacred Heart Medical Center and Children'S Hospital · Spokane, United States
Show 1 removed
  • Virginia Mason Medical Center · Seattle, United States
across 2 updates, Oct 9, 2026 – Oct 15, 2026
Primary completion
Nov 15, 2028→Oct 12, 2027
Nov 17, 2026
Study completion
May 14, 2029→Oct 12, 2027
Nov 17, 2026
Enrollment
466 (estimated)→13 (actual)
Nov 17, 2026
Show all 3 updates
  1. Nov 17, 2026
    Recruiting→Active, not recruiting
    Primary completion Nov 15, 2028→Oct 12, 2027
    Study completion May 14, 2029→Oct 12, 2027
    Enrollment 466 (estimated)→13 (actual)
    + 3 other changes: verification date, contact details and site details
  2. Oct 15, 2026
    1 site added
    Show site
    • Providence Sacred Heart Medical Center and Children'S Hospital · Spokane, United States
  3. Oct 9, 2026
    6 sites added, 1 site removed. 119 sites changed recruiting status (111 now completed, 8 now recruiting)
    Show 119 sites
    • Alaska Womens Cancer Care Akwcc · Anchorage, United StatesNot yet recruiting→Completed
    • University of Arizona Cancer Center · Tucson, United StatesNot yet recruiting→Completed
    • City of Hope Medical Center · Duarte, United StatesNot yet recruiting→Recruiting
    • Providence Medical Foundation · Fullerton, United StatesNot yet recruiting→Completed
    • University of California, San Diego-Moores Cancer Center · La Jolla, United StatesNot yet recruiting→Completed
    • Uci Health Chao Family Comprehensive Cancer Center · Orange, United StatesNot yet recruiting→Completed
    • Ventura County Hematology Oncology Specialists-Oxnard · Oxnard, United StatesNot yet recruiting→Completed
    • University of Colorado Cancer Center · Aurora, United StatesNot yet recruiting→Completed
    • Brcr Global · Miramar, United StatesNot yet recruiting→Completed
    • Sarasota Memorial Health Care System · Sarasota, United StatesNot yet recruiting→Completed
    • Winship Cancer Institute At Emory University · Atlanta, United StatesNot yet recruiting→Completed
    • Georgia Cancer Center · Augusta, United StatesNot yet recruiting→Completed
    • The University of Chicago Medicine · Chicago, United StatesNot yet recruiting→Completed
    • Carle Cancer Center · Effingham, United StatesNot yet recruiting→Completed
    • Northshore University Health System-Evanston Hospital · Evanston, United StatesNot yet recruiting→Completed
    • City of Hope - Chicago Cancer Center · Zion, United StatesNot yet recruiting→Completed
    • St Elizabeth Healthcare · Edgewood, United StatesNot yet recruiting→Completed
    • Maine Center For Cancer Medicine · Scarborough, United StatesNot yet recruiting→Completed
    • Holy Cross Hospital · Silver Spring, United StatesNot yet recruiting→Completed
    • Henry Ford Cancer - Detroit · Detroit, United StatesNot yet recruiting→Completed
    • Mercy Hospital St. Louis - David C. Pratt Cancer Center · St Louis, United StatesNot yet recruiting→Completed
    • Women'S Cancer Center of Nevada · Las Vegas, United StatesNot yet recruiting→Completed
    • Center of Hope · Reno, United StatesNot yet recruiting→Completed
    • Unm Comprehensive Cancer Center · Albuquerque, United StatesNot yet recruiting→Completed
    • East Carolina University · Greenville, United StatesNot yet recruiting→Completed
    • Cleveland Clinic Foundation · Cleveland, United StatesNot yet recruiting→Completed
    • Ohio Health Research Institute · Columbus, United StatesNot yet recruiting→Completed
    • Miami Valley Hospital South · Dayton, United StatesNot yet recruiting→Completed
    • Promedica Flower Hospital · Sylvania, United StatesNot yet recruiting→Completed
    • Providence Cancer Institute Franz Clinic · Portland, United StatesNot yet recruiting→Recruiting
    • …and 89 more on the registry record
    Show 6 added (6 United States)
    • Mount Sinai Medical Center Comprehensive Cancer Center · Miami Beach, United States
    • Greater Baltimore Medical Center · Towson, United States
    • Penn State Milton S. Hershey Medical Center · Hershey, United States
    • Texas Oncology Cancer Center · Austin, United States
    • Texas Oncology, P.A., San Antonio Medical Center - Uso · San Antonio, United States
    • Texas Oncology (Txo) Northeast Texas (Tyler) · Tyler, United States
    Show 1 removed
    • Virginia Mason Medical Center · Seattle, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07214779
Lead sponsor
Incyte Corporation
Collaborators
ENGOT Foundation, GOG Foundation
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Dec 9, 2025
Primary completion
Oct 12, 2027 (estimated)
Completion
Oct 12, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDK2 Inhibitor INCB123667

Start the discussion